See more : Emkay Global Financial Services Limited (EMKAY.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Achieve Life Sciences, Inc. (ACHV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Achieve Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hutchison Telecommunications Hong Kong Holdings Limited (0215.HK) Income Statement Analysis – Financial Results
- West Fraser Timber Co. Ltd. (WFG.TO) Income Statement Analysis – Financial Results
- Hang Tai Yue Group Holdings Limited (8081.HK) Income Statement Analysis – Financial Results
- Deinove SA (DNVVF) Income Statement Analysis – Financial Results
- LLA.L,0P0001T9GN,0 (LLA.L) Income Statement Analysis – Financial Results
Achieve Life Sciences, Inc. (ACHV)
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 8.75M | 408.41K | 12.10M | 5.10M | 18.90M | 16.60M | 4.50M | 1.10M |
| Cost of Revenue | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.22M | 3.69M | -600.00K | -800.00K | -600.00K | -500.00K | -300.00K | 5.50M |
| Gross Profit | -228.00K | -236.00K | -250.00K | -255.00K | -254.00K | -282.00K | -282.00K | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 3.53M | -3.28M | 12.70M | 5.90M | 19.50M | 17.10M | 4.80M | -4.40M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 40.33% | -803.51% | 104.96% | 115.69% | 103.17% | 103.01% | 106.67% | -400.00% |
| Research & Development | 15.81M | 30.08M | 23.97M | 6.88M | 9.67M | 5.87M | 3.10M | 14.79M | 25.11M | 46.22M | 55.32M | 39.95M | 21.55M | 18.48M | 24.16M | 7.82M | 27.15M | 41.10M | 24.49M | 10.71M | 7.65M | 8.96M | 5.22M | 3.26M | 5.60M | 10.50M | 11.60M | 11.20M | 7.20M | 0.00 |
| General & Administrative | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 0.00 | 5.84M | 3.96M | 3.29M | 8.22B | 7.58B | 5.57B | 5.87B | 3.01B | 3.24B | 3.31M | 3.95M | 5.78M | 6.55M | 7.20M | 3.81M | 2.20M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.21B | -7.57B | -5.56B | -5.86B | -3.01B | -3.24B | 888.00 | 432.52K | 720.00K | -50.00K | 0.00 | -10.00K | 0.00 | 0.00 |
| SG&A | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 6.23M | 5.84M | 3.96M | 3.29M | 8.22M | 7.58M | 5.57M | 5.87M | 3.01M | 3.24M | 3.31M | 4.38M | 6.50M | 6.50M | 7.20M | 3.80M | 2.20M | 3.50M |
| Other Expenses | 0.00 | -1.55M | -58.00K | -49.00K | 133.00K | 126.00K | 165.00K | 1.06M | 1.95M | 3.23M | 120.00K | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| Operating Expenses | 27.02M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.70M | 17.80M | 19.40M | 15.50M | 9.80M | 3.80M |
| Cost & Expenses | 27.25M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.10M | 17.00M | 18.80M | 15.00M | 9.50M | 9.30M |
| Interest Income | 825.00K | 199.00K | 17.00K | 69.00K | 170.00K | 171.00K | 21.00K | 203.00K | 119.00K | 35.00K | 150.00K | 292.00K | 220.00K | 86.00K | 47.00K | 210.00K | 2.30M | 2.85M | 714.87K | 289.59K | 213.19K | 468.48K | 539.69K | 692.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.85M | 1.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 531.00K | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 | 434.00 | 2.98K | 6.82K | 24.63K | 42.14K | 31.67K | 13.86K | 34.06K | 470.00K | 200.00K | 970.00K | 200.00K | 800.00K | 600.00K |
| Depreciation & Amortization | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 188.00K | 244.00K | 223.00K | 227.00K | 100.00K | 75.00K | 52.00K | 50.00K | 89.00K | 655.69K | 609.62K | 586.16K | 515.48K | 380.43K | 580.62K | 258.10K | 357.54K | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| EBITDA | -26.73M | -40.33M | -32.90M | -14.48M | -16.14M | -12.41M | -13.35M | -19.94M | -16.56M | -26.02M | -31.62M | -21.00M | -22.21M | -15.53M | 1.42M | -10.60M | -12.41M | -22.94M | -20.50M | -15.73M | -10.26M | -11.59M | 474.45K | -6.88M | 589.54K | -11.08M | 700.00K | 2.10M | -4.60M | -7.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -318.57% | -103.27% | -110.64% | -128.20% | -167.50% | -538.68% | -41.80% | -10.57% | -55.80% | -71.80% | -114.17% | -257.16% | -6.06% | -41,030.90% | -46,373.91% | 5.42% | -2,724.05% | 12.40% | -237.25% | -2.12% | 7.83% | -108.89% | -727.27% |
| Operating Income | -27.25M | -40.80M | -33.09M | -14.75M | -16.53M | -12.81M | -6.63M | -21.19M | -18.75M | -29.47M | -35.33M | -25.99M | -22.29M | -14.75M | -2.47M | -6.26M | -15.23M | -26.29M | -21.81M | -16.58M | -10.64M | -12.17M | 216.35K | -7.23M | 900.00K | -11.90M | 100.00K | 1.60M | -5.00M | -8.20M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -418.65% | -103.27% | -108.67% | -118.22% | -129.32% | -405.51% | -108.29% | -9.65% | -31.11% | -75.68% | -117.39% | -264.21% | -6.26% | -42,552.60% | -48,696.39% | 2.47% | -1,770.96% | 7.44% | -233.33% | 0.53% | 9.64% | -111.11% | -745.45% |
| Total Other Income/Expenses | -2.57M | -1.55M | -58.00K | 20.00K | 133.00K | 126.00K | -7.00M | -1.47M | 1.95M | 3.49M | 3.48M | 6.55M | 7.61M | -4.88M | 117.00K | 421.00K | 2.17M | 2.74M | 712.20K | -735.04K | 171.05K | 436.81K | 525.83K | 4.91M | 440.46K | 711.22K | 1.00M | 600.00K | -400.00K | -500.00K |
| Income Before Tax | -29.82M | -42.35M | -33.15M | -14.73M | -16.40M | -12.69M | -13.63M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -15.58M | 2.47M | -10.69M | -15.36M | -26.40M | -21.81M | -16.31M | -10.47M | -11.74M | 742.18K | -2.32M | 430.00K | -11.17M | 1.10M | 2.20M | -5.40M | -8.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -114.45% | 9.65% | -53.11% | -76.30% | -117.90% | -264.16% | -6.16% | -41,868.40% | -46,949.14% | 8.48% | -569.13% | 3.55% | -219.02% | 5.82% | 13.25% | -120.00% | -790.91% |
| Income Tax Expense | 0.00 | -475.00K | -250.00K | -69.00K | -254.00K | -126.00K | -3.05M | -1.06M | -1.95M | -3.49M | -3.48M | -6.55M | -7.61M | -3.00M | -3.01M | -2.06M | -2.17M | -2.74M | -712.20K | -264.96K | -171.05K | -101.48K | 200.00K | -176.94K | 470.00K | -730.00K | 100.00K | 500.00K | 500.00K | 200.00K |
| Net Income | -29.82M | -41.88M | -32.90M | -14.66M | -16.14M | -12.69M | -10.58M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -12.58M | 5.48M | -4.20M | -13.06M | -23.55M | -21.10M | -16.31M | -10.47M | -11.64M | 542.18K | -2.15M | 400.00K | -11.20M | 1.00M | 1.70M | -5.90M | -8.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -92.42% | 21.44% | -20.88% | -64.89% | -105.18% | -255.58% | -6.16% | -41,868.40% | -46,543.20% | 6.20% | -525.81% | 3.31% | -219.61% | 5.29% | 10.24% | -131.11% | -809.09% |
| EPS | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.48K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| EPS Diluted | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.47K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| Weighted Avg Shares Out | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.61K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
| Weighted Avg Shares Out (Dil) | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.65K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
Achieve Life Sciences Announces Participation at LD Micro Invitational Conference
SEATTLE and VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will...
Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will...
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Bencich - CEO & Director Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer...
Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update
Company to host conference call at 4:30 PM EDT today, May 12, 2022 Company to host conference call at 4:30 PM EDT today, May 12, 2022
Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation
Achieve Life Sciences Inc (NASDAQ: ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers. The 6- and 12-week cytisinicline treatments demonstrated significantly better.
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022
SEATTLE and VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will...
Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug
We are initiating ACHV with a buy rating and a target price of USD 70.
Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors
SEATTLE and VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce...
Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award
SEATTLE and VANCOUVER, British Columbia, March 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the...
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports